The innovative RHINISENG® and ERYSENG® PARVO vaccines are now available in South Korea. This was announced at the event that HIPRA organized at the end of April in Daejeon city (South Korea).

The Business Manager of the subsidiary, Myung-hyee Kim, was in charge of welcoming the act in which RHINISENG® was presented, the only registered vaccine against Progressive and Non-Progressive Atrophic Rhinitis and ERYSENG® PARVO, the new vaccine for the prevention of reproductive problems associated with Swine Erysipelas and Porcine Parvovirus.

In addition, the new concept of the TRUE FUSION was introduced, a unique combination between ERYSENG® PARVO and UNISTRAIN® PRRS

The event also featured two presentations by professors Young-soo Lyoo and Jeong-hee Han on the incidence and great impact that both atrophic rhinitis and reproductive diseases, respectively, cause in the Korean swine industry today.

This launch materializes the arrival of two new products to Korea, ERYSENG® PARVO and RHINISENG® which, together with SUISENG®, complete the SENG RANGE as "the most modern and complete range of vaccines for breeders", reinforcing HIPRA's commitment to continue to be the reference in prevention.